Article Text

Download PDFPDF

Effective immunosuppressive therapy in a patient with primary pulmonary hypertension
Free
  1. F Bellottoa,
  2. P Chiavaccia,
  3. F Lavederb,
  4. A Angelinic,
  5. G Thienec,
  6. R Marcolongob
  1. aCardiology Division, bClinical Immunology Branch, cCardiac Pathology, dPadua University School of Medicine, Italy
  1. Dr R Marcolongo, Università degli Studi di Padova, Dipartimento di Medicina Clinica e Sperimentale, Servizio di Immunologia Clinica, Via Giustiniani 2, 35128 Padova, Italy.

Abstract

The case history is described of a young woman who presented with primary pulmonary hypertension and non-specific inflammatory signs. The patient received prolonged immunosuppressive treatment with low dose methotrexate and prednisone without any vasodilator agent. After one year the pulmonary artery pressure fell from a mean value of 47 mm Hg to 30 mm Hg and there was a corresponding clinical response. This case suggests that, in patients with pulmonary hypertension of unknown origin, immunopathogenetic factors should be sought in order to consider the utility of immunosuppressive therapy.

  • pulmonary hypertension
  • methotrexate
  • transforming growth factor β

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.